Advertisement
Product › Details
Cimzia®
Next higher product group | certolizumab pegol (CDP870) | |
Status | 2012-08-01 sales existent | |
Annual sales | USD 760,000,000 (sales (2013) 2013) | |
Record changed: 2023-07-10 |
Advertisement
More documents for MAb
- [1] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
- [2] Elicera Therapeutics AB. (3/22/21). "Press Release: Elicera Announces Appointment of ATMP Specialist Karin Hoogendoorn to the Board". Gothenburg....
- [3] Argen-X N.V. (Argenx). (4/9/18). "Press Release: Argenx Appoints Keith Woods as Chief Operating Officer". Breda & Ghent....
- [4] Mundipharma International Ltd.. (6/14/17). "Press Release: New Data Show Truxima (CT-P10) to Have Comparable Efficacy and Tolerability in Advanced Follicular Lymphoma to Reference i.v. Rituximab". Cambridge....
- [5] Napp Pharmaceuticals Ltd.. (2/24/17). "Press Release: Napp Launches Truxima (rituximab), the First Biosimilar Monoclonal Antibody for the Treatment of Cancer, in the UK". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top